IL158041A0 - Benzimidazole derivatives and pharmaceutical compositions containing the same - Google Patents

Benzimidazole derivatives and pharmaceutical compositions containing the same

Info

Publication number
IL158041A0
IL158041A0 IL15804102A IL15804102A IL158041A0 IL 158041 A0 IL158041 A0 IL 158041A0 IL 15804102 A IL15804102 A IL 15804102A IL 15804102 A IL15804102 A IL 15804102A IL 158041 A0 IL158041 A0 IL 158041A0
Authority
IL
Israel
Prior art keywords
same
pharmaceutical compositions
compositions containing
benzimidazole derivatives
benzimidazole
Prior art date
Application number
IL15804102A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL158041A0 publication Critical patent/IL158041A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL15804102A 2001-03-28 2002-03-26 Benzimidazole derivatives and pharmaceutical compositions containing the same IL158041A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27932701P 2001-03-28 2001-03-28
PCT/US2002/009402 WO2002079192A1 (fr) 2001-03-28 2002-03-26 Nouveaux inhibiteurs de la tyrosine kinase

Publications (1)

Publication Number Publication Date
IL158041A0 true IL158041A0 (en) 2004-03-28

Family

ID=23068491

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15804102A IL158041A0 (en) 2001-03-28 2002-03-26 Benzimidazole derivatives and pharmaceutical compositions containing the same

Country Status (25)

Country Link
EP (1) EP1381598A4 (fr)
JP (1) JP2004534010A (fr)
KR (1) KR20030083016A (fr)
CN (1) CN1514833A (fr)
AR (1) AR035804A1 (fr)
BG (1) BG108206A (fr)
BR (1) BR0208373A (fr)
CA (1) CA2442428A1 (fr)
CZ (1) CZ20032615A3 (fr)
EE (1) EE200300475A (fr)
GE (1) GEP20053660B (fr)
HR (1) HRP20030844A2 (fr)
HU (1) HUP0400323A2 (fr)
IL (1) IL158041A0 (fr)
IS (1) IS6968A (fr)
MX (1) MXPA03008690A (fr)
NO (1) NO20034308L (fr)
PE (1) PE20021015A1 (fr)
PL (1) PL373300A1 (fr)
RU (1) RU2003131693A (fr)
SK (1) SK12002003A3 (fr)
UY (1) UY27234A1 (fr)
WO (1) WO2002079192A1 (fr)
YU (1) YU84603A (fr)
ZA (1) ZA200307466B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2003073841A2 (fr) 2002-03-01 2003-09-12 Bristol-Myers Squibb Company Mammiferes transgeniques non humains exprimant des recepteurs de la tyrosine kinase a activation constitutive
CA2488635C (fr) * 2002-06-12 2012-10-23 Abbott Laboratories Antagonistes du recepteur de l'hormone de melano-concentration
EP1575580A4 (fr) * 2002-12-02 2009-06-10 Arqule Inc Methodes de traitement de cancers
EP1581539A4 (fr) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Nouveaux inhibiteurs de tyrosine kinase
US7329678B2 (en) * 2003-01-28 2008-02-12 Smithkline Beecham Corporation Chemical compounds
US7312215B2 (en) 2003-07-29 2007-12-25 Bristol-Myers Squibb Company Benzimidazole C-2 heterocycles as kinase inhibitors
EP1663204B1 (fr) 2003-08-29 2014-05-07 Exelixis, Inc. Modulateurs c-kit et leurs procedes d'utilisation
US20050075358A1 (en) * 2003-10-06 2005-04-07 Carboni Joan M. Methods for treating IGF1R-inhibitor induced hyperglycemia
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
CN102924458B (zh) 2004-04-02 2014-11-05 Osi制药有限责任公司 6,6-双环取代的杂双环蛋白激酶抑制剂
CA2591413A1 (fr) * 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones utiles comme inhibiteurs de proteine kinases de la famille tec pour le traitement de maladies inflammatoires, proliferatives et a mediation immunologique
WO2006130657A2 (fr) 2005-05-31 2006-12-07 Bristol-Myers Squibb Company Procede de reduction stereoselective pour la preparation de composes de pyrrolotriazine
US8088928B2 (en) 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
WO2007019417A1 (fr) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Dérivés d’oxazolopyridine comme modulateurs du sirtuin
AU2006285038A1 (en) * 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated 3,5-disubstituted pyrid-2-ones useful as inhibitors of Tec family of non-receptor tyrosine kinases
WO2007027528A2 (fr) 2005-08-29 2007-03-08 Vertex Pharmaceuticals Incorporated Utilisation de pyridones en tant qu'inhibiteurs de kinases
ATE528302T1 (de) * 2005-08-29 2011-10-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind
WO2007026720A1 (fr) * 2005-08-31 2007-03-08 Taisho Pharmaceutical Co., Ltd. Derive de pyrazole a noyau condense
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
WO2007145203A1 (fr) * 2006-06-13 2007-12-21 Daiichi Fine Chemical Co., Ltd. 2-amino-1-(4-fluorophenyl) éthanol optiquement actif
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
WO2008022747A1 (fr) * 2006-08-21 2008-02-28 F. Hoffmann-La Roche Ag Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques
WO2008025526A1 (fr) * 2006-08-31 2008-03-06 F. Hoffmann-La Roche Ag Dérivés d'indole, fabrication de ceux-ci et utilisation comme agents pharmaceutiques
WO2008144345A2 (fr) 2007-05-17 2008-11-27 Bristol-Myers Squibb Company Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
CN101687840A (zh) * 2007-06-25 2010-03-31 霍夫曼-拉罗奇有限公司 作为激酶抑制剂的苯并咪唑酰胺基衍生物
EP2065380A1 (fr) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer
US7816540B2 (en) * 2007-12-21 2010-10-19 Hoffmann-La Roche Inc. Carboxyl- or hydroxyl-substituted benzimidazole derivatives
CN101970424B (zh) 2008-01-22 2013-06-12 弗奈利斯(R&D)有限公司 具有检测点激酶1抑制活性的吲哚基吡啶酮衍生物
JP2011520970A (ja) 2008-05-19 2011-07-21 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換されたイミダゾピラジン類およびイミダゾトリアジン類
EA021424B1 (ru) 2008-12-19 2015-06-30 Сертрис Фармасьютикалз, Инк. Тиазолопиридиновые соединения, регулирующие сиртуин
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
CA2752826A1 (fr) 2009-04-20 2010-10-28 OSI Pharmaceuticals, LLC Preparation de c-pyrazine-methylamines
EP2435435B1 (fr) * 2009-05-27 2014-01-29 AbbVie Inc. Inhibiteurs pyrimidines de l'activité kinase
EP2494070A2 (fr) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
NZ608069A (en) * 2010-10-06 2014-06-27 Glaxosmithkline Llc Benzimidazole derivatives as pi3 kinase inhibitors
JP5789888B2 (ja) * 2010-11-01 2015-10-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のベンゾイミダゾールインヒビター
EP2766497A1 (fr) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
BR112015031073B1 (pt) 2013-06-21 2022-11-29 Zenith Epigenetics Ltd Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
CN103936719A (zh) * 2014-05-14 2014-07-23 中国药科大学 苯并咪唑类衍生物制备方法及用途
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016092375A1 (fr) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Hétérocycles substitués à titre d'inhibiteurs de bromodomaines
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
US10179777B2 (en) * 2015-04-16 2019-01-15 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives
EP3914698A1 (fr) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Milieux de culture pour cellules souches pluripotentes
CN117069696B (zh) * 2023-08-17 2024-04-26 中国药科大学 一种双靶点小分子抑制剂及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) * 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
RS50340B (sr) * 1999-06-23 2009-11-10 Sanofi-Aventis Deutschland Gmbh., Supstituisani benzimidazoli
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors

Also Published As

Publication number Publication date
PL373300A1 (en) 2005-08-22
CZ20032615A3 (en) 2004-03-17
JP2004534010A (ja) 2004-11-11
NO20034308L (no) 2003-11-26
PE20021015A1 (es) 2002-11-10
UY27234A1 (es) 2002-10-31
EP1381598A4 (fr) 2008-03-19
HUP0400323A2 (hu) 2005-11-28
YU84603A (sh) 2006-03-03
CA2442428A1 (fr) 2002-10-10
BR0208373A (pt) 2005-02-22
MXPA03008690A (es) 2003-12-12
GEP20053660B (en) 2005-11-10
NO20034308D0 (no) 2003-09-26
RU2003131693A (ru) 2005-05-10
HRP20030844A2 (en) 2005-08-31
SK12002003A3 (en) 2004-10-05
ZA200307466B (en) 2005-01-13
AR035804A1 (es) 2004-07-14
CN1514833A (zh) 2004-07-21
IS6968A (is) 2003-09-26
BG108206A (bg) 2004-11-30
EE200300475A (et) 2004-02-16
KR20030083016A (ko) 2003-10-23
WO2002079192A1 (fr) 2002-10-10
EP1381598A1 (fr) 2004-01-21

Similar Documents

Publication Publication Date Title
IL158041A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL161616A0 (en) Indazolypyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL158044A0 (en) Cyclopropylindole derivatives and pharmaceutical compositions containing the same
IL158300A0 (en) Bisarylimidazol derivatives and pharmaceutical compositions containing the same
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL162548A0 (en) 4-Oxoquinoline derivatives and pharmaceutical compositions containing the same
IL166482A0 (en) Dihydropyrazolopyridine derivatives and pharmaceutical compositions containing the same
IL158076A0 (en) Benzamidine derivatives and pharmaceutical compositions containing the same
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
IL159725A0 (en) Pharmaceutical compositions containing benzimidazole derivatives
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL156812A0 (en) Phthalazinone-piperidino derivatives and pharmaceutical compositions containing the same
IL153123A0 (en) N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
IL158523A0 (en) Epothilone derivatives and pharmaceutical compositions containing the same
IL157131A0 (en) Nitrogen containing heterocyclic derivatives and pharmaceutical compositions containing the same
IL164209A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL166620A0 (en) Pyrazole derivatives and pharmaceutical compositions containing the same
IL173602A0 (en) Heteroarylaminosulfonylphenyl derivatives and pharmaceutical compositions containing the same
IL173627A0 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives and pharmaceutical compositions containing the same
HUP0400467A3 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
IL173051A0 (en) N-glucoside derivatives and pharmaceutical compositions containing the same
IL171997A0 (en) Pyrrolodihydroisoquinoline derivatives and pharmaceutical compositions containing the same
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
IL175214A0 (en) 2-cyanopyrrolidinecarboxamide derivatives and pharmaceutical compositions containing the same